BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 5.05.2022

Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies." This draft guidance describes the FDA's recommendations regarding clinical pharmacology considerations for conducting human radiolabeled mass balance studies, including deciding whether and when to conduct the study, designing the study, and reporting results.

Source: Federal Register — Food and Drug AdministrationOpen original release →